It has previously been shown that in vivo treatment of MOC2 tumors in a murine HNSCC model with PD-1 and CTLA-4 blockade does not confer increased anti-tumor immunity or increased presence of CD8+ tumor-infiltrating lymphocytes [28]. This evidence concerns the gene CTLA4 and head and neck squamous cell carcinoma.